SUMMARY Two cases of neonatal hepatitis are described, one related to cytomegalovirus infection and the other idiopathic. In both infants a transient abnormality of the a1-antitrypsin phenotype, inconsistent with the parent's phenotypes, reverted to normal during the convalescent phase of the illness.
abnormality of the a1-antitrypsin phenotype, inconsistent with the parent's phenotypes, reverted to normal during the convalescent phase of the illness.
Case 1 A girl of 36 weeks' gestation, who weighed only 1015 g at birth, developed a conjugated hyperbilirubinaemia from her third day of life. Her mother had had a non-specific viral illness with a rash at about 24 to 26 weeks' gestation.
Investigation showed evidence of cytomegalovirus infection in urine culture and throat swab. Both mother and child had a cytomegalovirus titre of 40 by complement fixation. Other virology and toxoplasma titres were negative. In addition she had an a1-antitrypsin titre of 1-7 g/l (normal range 1-8 to 3-0 g/l) with a PiMZ phenotype, despite both parents being PiM. She reverted to a PiM phenotype by the age of 11 months.
Her developmental progress has been mildly delayed with bilateral hearing impairment and poor growth. There is no evidence of persisting hepatic pathology at the age of 2 years. Investigation showed a normal hepatic ultrasound, negative virology and toxoplasma titres, and negative urine culture for cytomegalovirus. The urine showed no notable increase in reducing substances. His a,-antitrypsin value was 1-3 g/l (normal range 1-8 to 3-0 g/l) with a PiMZ phenotype. His parents' phenotypes were P1M. During the convalescent phase, at the age of 10 months, when his liver function tests had returned to normal, his phenotype reverted to P1M with an a1-antitrypsin value of 1-9 g/l.
He has persisting poor growth, but his development seems to be progressing satisfactorily. Constitutional delay of growth occurs in otherwise healthy adolescents with stature reduced for chronological age but generally appropriate for bone age and the stage of pubertal development, both of which are usually delayed. There is often considerable delay in the onset of the puberty growth spurt which may cause severe psychological disturbance.
Oxandrolone (172-hydroxy-17-methyl-2-oxa-52-androstan-3-one) is one of a group of anabolic steroids derived from testosterone which accelerate growth.' Their use in the treatment of short stature has fallen into disrepute because of potential side effects. These include virilisation, suppression of the hypothalamic-pituitary axis, and hepatotoxicity but the most serious problem is the potential to advance bone age disproportionately to height gain, which compromises final adult height. The poor reputation that anabolic steroids have gained may partly be due to the large doses which were first used.' Growth acceleration does not seem to be related to dose but advance in skeletal maturation is.1 We have attempted to define an effective treatment regimen, free of side effects, using oxandrolone.
Patients and methods
Twenty four, short, pubertal boys (testicular volumes more than 3 ml) were treated with oxandrolone because of severe psychological disturbance. Two had mild asthma and one had severe psoriasis which had been treated with topical fluorinated corticosteroids. The heights of all patients were less than the 3rd centile for chronological age, except for one, whose height was on the 10th centile. Fourteen had delayed puberty with testicular volumes less than the 10th centile for chronological age. 
